Arcus Biosciences, Inc. — Director's Dealing 2020

Aug 11, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2020-08-07

Reporting Person: ROSEN TERRY J (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-08-07	Common Stock	P	11655	$21.4424	Acquired	3199129	Indirect
2020-08-10	Common Stock	P	32050	$23.3823	Acquired	3231179	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	189393	Direct
Common Stock	398350	Indirect
Common Stock	437315	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.11 to $21.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2: 101,650 and 62,685 shares previously held by the reporting person in Rosen GRAT No. 1 and No. 2, respectively, were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13.

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.69 to $23.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.